Acumen Pharmaceuticals, Inc. (ABOS) stock
ABOSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.19−0.04 (-15.51%)
Close on Nov 18, 2026Market cap $14.06MP/E –Yield –
Acumen Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Acumen Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was -$104.72M. For fiscal 2025 it was -$123.83M. The highest annual figure on record is -$7.91M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$123.83M | – |
| FY2024 | Dec 31, 2024 | -$114.02M | – |
| FY2023 | Dec 31, 2023 | -$61.14M | – |
| FY2022 | Dec 31, 2022 | -$45.24M | – |
| FY2021 | Dec 31, 2021 | -$19.58M | – |
| FY2020 | Dec 31, 2020 | -$7.91M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$25.81M | – |
| Q2 FY2026 | Jun 30, 2026 | -$32.56M | – |
| Q1 FY2026 | Mar 31, 2026 | -$21.15M | – |
| Q4 FY2025 | Dec 31, 2025 | -$25.20M | – |
| Q3 FY2025 | Sep 30, 2025 | -$26.51M | – |
| Q2 FY2025 | Jun 30, 2025 | -$41.75M | – |
| Q1 FY2025 | Mar 31, 2025 | -$30.37M | – |
| Q4 FY2024 | Dec 31, 2024 | -$39.60M | – |
| Q3 FY2024 | Sep 30, 2024 | -$32.27M | – |
| Q2 FY2024 | Jun 30, 2024 | -$24.38M | – |
| Q1 FY2024 | Mar 31, 2024 | -$17.77M | – |
| Q4 FY2023 | Dec 31, 2023 | -$18.49M | – |
| Q3 FY2023 | Sep 30, 2023 | -$16.04M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.48M | – |
| Q1 FY2023 | Mar 31, 2023 | -$13.14M | – |
| Q4 FY2022 | Dec 31, 2022 | -$14.25M | – |
| Q3 FY2022 | Sep 30, 2022 | -$11.37M | – |
| Q2 FY2022 | Jun 30, 2022 | -$10.41M | – |
| Q1 FY2022 | Mar 31, 2022 | -$9.21M | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.42M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.94M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.44M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.79M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.34M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.49M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.04M | – |
See a number that looks wrong?